These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22303018)

  • 21. Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb.
    Georgoutsou-Spyridonos M; Ricklin D; Pratsinis H; Perivolioti E; Pirmettis I; Garcia BL; Geisbrecht BV; Foukas PG; Lambris JD; Mastellos DC; Sfyroera G
    J Immunol; 2015 Oct; 195(8):3946-58. PubMed ID: 26342032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunological comparison of Efb and ClfA of Staphylococcus aureus isolated from bovine].
    Liu Y; Sul Y; Zhang B; Su L; Jiang H
    Sheng Wu Gong Cheng Xue Bao; 2015 Sep; 31(9):1335-43. PubMed ID: 26955711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of protein A in the evasion of host adaptive immune responses by Staphylococcus aureus.
    Falugi F; Kim HK; Missiakas DM; Schneewind O
    mBio; 2013 Aug; 4(5):e00575-13. PubMed ID: 23982075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential epitope recognition in the immunodominant staphylococcal antigen A of Staphylococcus aureus by mouse versus human IgG antibodies.
    Koedijk DGAM; Pastrana FR; Hoekstra H; Berg SVD; Back JW; Kerstholt C; Prins RC; Bakker-Woudenberg IAJM; van Dijl JM; Buist G
    Sci Rep; 2017 Aug; 7(1):8141. PubMed ID: 28811514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins.
    Hazenbos WL; Kajihara KK; Vandlen R; Morisaki JH; Lehar SM; Kwakkenbos MJ; Beaumont T; Bakker AQ; Phung Q; Swem LR; Ramakrishnan S; Kim J; Xu M; Shah IM; Diep BA; Sai T; Sebrell A; Khalfin Y; Oh A; Koth C; Lin SJ; Lee BC; Strandh M; Koefoed K; Andersen PS; Spits H; Brown EJ; Tan MW; Mariathasan S
    PLoS Pathog; 2013; 9(10):e1003653. PubMed ID: 24130480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective opsonic activity of antibodies against fibronectin-binding proteins (FnBPs) of Staphylococcus aureus.
    Rozalska B; Wadström T
    Scand J Immunol; 1993 May; 37(5):575-80. PubMed ID: 8484103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild Staphylococcus aureus Skin Infection Improves the Course of Subsequent Endogenous S. aureus Bacteremia in Mice.
    van den Berg S; de Vogel CP; van Belkum A; Bakker-Woudenberg IA
    PLoS One; 2015; 10(6):e0129150. PubMed ID: 26060995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.
    Kuipers A; Stapels DAC; Weerwind LT; Ko YP; Ruyken M; Lee JC; van Kessel KPM; Rooijakkers SHM
    Microbiology (Reading); 2016 Jul; 162(7):1185-1194. PubMed ID: 27112346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease.
    Tkaczyk C; Hamilton MM; Sadowska A; Shi Y; Chang CS; Chowdhury P; Buonapane R; Xiao X; Warrener P; Mediavilla J; Kreiswirth B; Suzich J; Stover CK; Sellman BR
    mBio; 2016 Jun; 7(3):. PubMed ID: 27353753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective immunization against Staphylococcus aureus infection in a novel experimental wound model in mice.
    Schennings T; Farnebo F; Szekely L; Flock JI
    APMIS; 2012 Oct; 120(10):786-93. PubMed ID: 22958286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of complement activation by a secreted Staphylococcus aureus protein.
    Lee LY; Höök M; Haviland D; Wetsel RA; Yonter EO; Syribeys P; Vernachio J; Brown EL
    J Infect Dis; 2004 Aug; 190(3):571-9. PubMed ID: 15243934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization routes in cattle impact the levels and neutralizing capacity of antibodies induced against S. aureus immune evasion proteins.
    Boerhout E; Vrieling M; Benedictus L; Daemen I; Ravesloot L; Rutten V; Nuijten P; van Strijp J; Koets A; Eisenberg S
    Vet Res; 2015 Sep; 46():115. PubMed ID: 26411347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin.
    Brown EL; Bowden MG; Bryson RS; Hulten KG; Bordt AS; Forbes A; Kaplan SL
    Clin Vaccine Immunol; 2009 Jan; 16(1):139-41. PubMed ID: 19005019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective Identification of a Broad IgG Repertoire Differentiating Patients With
    Rigat F; Bartolini E; Dalsass M; Kumar N; Marchi S; Speziale P; Maione D; Chen L; Romano MR; Alegre ML; Bagnoli F; Daum RS; David MZ
    Front Immunol; 2019; 10():114. PubMed ID: 30792711
    [No Abstract]   [Full Text] [Related]  

  • 35. A novel peptide can mimic extracellular fibrinogen-binding protein to block the activation of complement system.
    Gao YP; Dong J; Zhang X; Liu Y; Lu Q; Feng JN; Tan XR; Yang G
    Cell Biochem Biophys; 2013 Jul; 66(3):753-7. PubMed ID: 23420525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN.
    Hoekstra H; Romero Pastrana F; Bonarius HPJ; van Kessel KPM; Elsinga GS; Kooi N; Groen H; van Dijl JM; Buist G
    Virulence; 2018 Jan; 9(1):70-82. PubMed ID: 28277903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The TLR2 Antagonist Staphylococcal Superantigen-Like Protein 3 Acts as a Virulence Factor to Promote Bacterial Pathogenicity in vivo.
    Koymans KJ; Goldmann O; Karlsson CAQ; Sital W; Thänert R; Bisschop A; Vrieling M; Malmström J; van Kessel KPM; de Haas CJC; van Strijp JAG; Medina E
    J Innate Immun; 2017; 9(6):561-573. PubMed ID: 28858870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).
    Wood JB; Jones LS; Soper NR; Nagarsheth M; Creech CB; Thomsen IP
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins.
    Romero Pastrana F; Neef J; Koedijk DGAM; de Graaf D; Duipmans J; Jonkman MF; Engelmann S; van Dijl JM; Buist G
    Sci Rep; 2018 Feb; 8(1):3234. PubMed ID: 29459694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive immune response to lipoproteins of Staphylococcus aureus in healthy subjects.
    Vu CH; Kolata J; Stentzel S; Beyer A; Gesell Salazar M; Steil L; Pané-Farré J; Rühmling V; Engelmann S; Götz F; van Dijl JM; Hecker M; Mäder U; Schmidt F; Völker U; Bröker BM
    Proteomics; 2016 Oct; 16(20):2667-2677. PubMed ID: 27324828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.